{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:31:50Z","timestamp":1765827110934},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T00:00:00Z","timestamp":1379548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10557-013-6491-8","type":"journal-article","created":{"date-parts":[[2013,9,18]],"date-time":"2013-09-18T06:16:56Z","timestamp":1379485016000},"page":"73-77","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuya","family":"Matsue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Nagahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Tejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumizu","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Okishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,19]]},"reference":[{"key":"6491_CR1","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","volume":"115","author":"W Rosamond","year":"2007","unstructured":"Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics\u20142007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69\u2013e171.","journal-title":"Circulation"},{"key":"6491_CR2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","volume":"77","author":"N Sato","year":"2013","unstructured":"Sato N, Kajimoto K, Keida T, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J. 2013;77:944\u201351.","journal-title":"Circ J"},{"key":"6491_CR3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"6491_CR4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2215\/CJN.03150509","volume":"4","author":"M Sarraf","year":"2009","unstructured":"Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol. 2009;4:2013\u201326.","journal-title":"Clin J Am Soc Nephrol"},{"key":"6491_CR5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cardfail.2009.11.005","volume":"16","author":"MR Thomson","year":"2010","unstructured":"Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16:188\u201393.","journal-title":"J Card Fail"},{"key":"6491_CR6","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.CCM.0000296272.68078.6B","volume":"36","author":"DJ Wang","year":"2008","unstructured":"Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med. 2008;36:S89\u201394.","journal-title":"Crit Care Med"},{"key":"6491_CR7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1172\/JCI112187","volume":"76","author":"V Kon","year":"1985","unstructured":"Kon V, Yared A, Ichikawa I. Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular fluid volume depletion. J Clin Invest. 1985;76:1913\u201320.","journal-title":"J Clin Invest"},{"key":"6491_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1\u201313.","journal-title":"Cardiovasc Drug Rev"},{"key":"6491_CR9","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Ren Physiol. 2006;290:F273\u20138.","journal-title":"Am J Physiol Ren Physiol"},{"key":"6491_CR10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"6491_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169\u201374.","journal-title":"J Cardiol"},{"key":"6491_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","volume":"147","author":"J Butler","year":"2004","unstructured":"Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331\u20138.","journal-title":"Am Heart J"},{"key":"6491_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","volume":"43","author":"DE Forman","year":"2004","unstructured":"Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"6491_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cardfail.2006.02.007","volume":"12","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail. 2006;12:257\u201362.","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"6491_CR15","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25 Suppl 1:S33\u201345.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6491_CR16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jjcc.2012.09.002","volume":"60","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462\u20139.","journal-title":"J Cardiol"},{"key":"6491_CR17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"6491_CR18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"key":"6491_CR19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541\u20137.","journal-title":"JAMA"},{"key":"6491_CR20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883\u201391.","journal-title":"JAMA"},{"key":"6491_CR21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurheartj\/ehp458","volume":"31","author":"A Mebazaa","year":"2010","unstructured":"Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010;31:832\u201341.","journal-title":"Eur Heart J"},{"key":"6491_CR22","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/CIR.0b013e3181f9a223","volume":"122","author":"NL Weintraub","year":"2010","unstructured":"Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122:1975\u201396.","journal-title":"Circulation"},{"issue":"suppl 1","key":"6491_CR23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","volume":"23","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, et al. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011;23 suppl 1:S19\u201331.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-013-6491-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-013-6491-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-013-6491-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:28:18Z","timestamp":1559237298000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-013-6491-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["6491"],"URL":"https:\/\/doi.org\/10.1007\/s10557-013-6491-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,19]]}}}